Page 170 - புனே அடிப்படையிலானது சீரம் நிறுவனம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

16,000 medical staff trained in Maharashtra for vaccine drive: Rajesh Tope

16,000 medical staff trained in Maharashtra for vaccine drive: Rajesh Tope
mid-day.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mid-day.com Daily Mail and Mail on Sunday newspapers.

United kingdomNational institute of virologySerum institute of indiaHealth minister rajesh topePune based national institutePune based serum instituteஒன்றுபட்டது கிஂக்டம்தேசிய நிறுவனம் ஆஃப் வைராலஜிசீரம் நிறுவனம் ஆஃப் இந்தியாஆரோக்கியம் அமைச்சர் ராஜேஷ் தோப்பேபுனே அடிப்படையிலானது தேசிய நிறுவனம்புனே அடிப்படையிலானது சீரம் நிறுவனம்

Bharat Biotech to submit additional data for vaccine s emergency approval

Bharat Biotech to submit additional data for vaccine s emergency approval
daijiworld.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from daijiworld.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomNew delhiIndian council of medical researchCentral drugs standard control organizationSerum institute of indiaRegulatory agencyHyderabad based bharat biotechIndian councilMedical researchDrug controller generalSerum institutePune based serum instituteஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்புதியது டெல்ஹி

Coronavirus outbreak: Bharat Biotech s Covaxin generates dual immune response

India’s homegrown candidate vaccine against the novel coronavirus disease developed by the Hyderabad-based Bharat Biotech has generated a dual immune response that has raised hopes of immunity lasting six to 12 months. The candidate vaccine named Covaxin generated anti-coronavirus antibodies and stirred immune memory cells in the vaccinated volunteers, researchers with Bharat Biotech and the Indian Council of Medical Research said in a scientific paper released on Wednesday. The paper, describing the results of safety and immunogenicity trials in 380 volunteers in nine hospitals across the country, has also reported similar immune responses across age groups. The trials offered the candidate vaccine to volunteers aged between 12 years up to 65 years.

University of pennsylvaniaUnited statesNew delhiShankar musunuriTanmay majumdarKrishna ellaHarvey rubinNational institute of virologyNational institute of immunologyIndian council of medical researchOcugen incSerum institute of indiaHyderabad based bharat biotechBharat biotechIndian councilMedical research

Bharat Biotech to Submit Additional Data for Covid-19 Vaccine s Emergency Approval

Bharat Biotech Has Again Applied for Emergency Authorisation of Covid-19 Vaccine, Say Sources FOLLOW US ON: Hyderabad-based Bharat Biotech has applied for Emergency Use Authorisation of its Covid-19 vaccine COVAXIN again with the Drug Controller General of India (DCGI), sources told News18 on Wednesday. COVAXIN, an inactivated vaccine candidate, is currently undergoing Phase III human clinical trials on 26,000 volunteers at 25 centres across India, after having undergone Phase I and II trials involving 1,000 volunteers. Bharat Biotech had applied for the emergency use authorisation of its vaccine on December 7 and presented its proposal for the grant, along with the interim safety and immunogenicity data of Phase I and II clinical trials.

United statesUnited kingdomIndian council of medical researchCentral drugs standard control organizationSerum institute of indiaRegulatory agencyHyderabad based bharat biotechIndian councilMedical researchDrug controller generalSerum institutePune based serum instituteஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்இந்தியன் சபை ஆஃப் மருத்துவ ஆராய்ச்சிமைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந்

Serum seeks marketing nod for Covishield

Serum seeks marketing nod for Covishield SECTIONS Share Synopsis The SII application appears to be lacking the immunogenicity data from the phase-3 trials which experts say as per timelines would not have been ready by now. Getty Images AstraZeneca-Oxford University proposal for emergency use authorisation is currently under evaluation with the UK regulator. New Delhi: Pune-based Serum Institute of India (SII) has approached India’s drug regulator once again seeking marketing authorisation for its potential Covid-19 vaccine. The firm has submitted updated data as required by the expert panel, people in the know told ET. “SII has submitted full dose efficacy data of the UK trials and safety data from its own phase-3 trials which are ongoing in India,” said one of these people.

United kingdomHimachal pradeshNew delhiVinod paulAstrazenca oxford universityAstrazeneca oxford universitySerum instituteCentral drug laboratorySerum institute of indiaPune based serum instituteBharat biotechZeneca oxford universityஒன்றுபட்டது கிஂக்டம்கச ul லிஇமாச்சல் பிரதேஷ்புதியது டெல்ஹி